Statistical Considerations for Multiplicity in Confirmatory Protocols

Therapeutic Innovation & Regulatory Science

Volumn 30, Issue 2, 1996, Pages 523-534

  Koch, Gary G ^a   Gansky, Stuart A ^a  

^a University of North Carolina at Chapel Hill   (United States)

Author keywords

Closed testing procedure; ; Multiple endpoints; Multiple treatments; Significance level spending function; Subgroups

Indexed keywords

EID: 84993725088     PISSN: 21684790     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159603000228     Document Type: Article

References (26)

1. Koch GG Amara IA Forster J McSorley D Peace KE. Statistical issues in the design and analysis of ulcer healing and recurrence studies. Drug Inf J. 1993; 17: 805–824.
2. Elashoff JD Koch GG. Statistical methods in trials of anti-ulcer drugs. In: Swabb EA, Szabo S, eds. Ulcer Disease Investigation and Basis for Therapy. New York: Marcel Dekker, Inc.; 1991: 375–406.
3. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics. 1984; 40: 1079–1087.
4. Lehmacher W Wassmer G Reitmeir P. Procedures for two-sample comparisons with multiple endpoints controlling the experimentwise error rate. Biometrics. 1991; 47: 511–521.
5. Koch GG Carr GJ Amara IA Stokes ME Uryniak TJ. Categorical data analysis. In: Berry DA, ed. Statistical Methodology in the Pharmaceutical Sciences. New York: Marcel Dekker, Inc.; 1990; 389–473.
6. Koch GG. Comment. Stat Med. 1991; 10: 13–16.
7. Bauer P. Multiple testing in clinical trials. Stat Med. 1991; 10: 871–890.
8. Gansky SA Koch GG Wilson J. Statistical evaluation of relationships between analgesic dose and ordered ratings of pain relief over an eight-hour period. J Biopharm Stat. 1994; 4(2):233–265.
9. Phillips JA Cairns V Koch GG. The analysis of a multiple-dose, combination-drug clinical trial using response surface methodology. J Biopharm Stat. 1992; 2(1):49–67.
10. Koch GG. Discussion. Biopharm Report. 1993; 2(1):7–8.
11. O'Brien PC Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979; 35: 549–556.
12. DeMets DL Lan KKG. Interim analysis: The alpha spending function approach. Stat Med. 1994; 13(13/14):1341–1352.
13. Koch GG Edward S. Clinical efficacy trials with categorical data. In: Peace KE, ed. Biopharmaceutical Statistics for Drug Development. New York: Marcel Dekker; 1988: 403–457.
14. Mantel N Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22: 719–748.
15. Mantel N. Chi-square tests with one degree of freedom: Extensions of the Mantel-Haenszel procedure. J Am Stat Assoc. 1963; 58: 690–700.
16. Koch GG Amara IA Davis GW Gillings DB. A review of some statistical methods for covariance analysis of categorical data. Biometrics. 1982; 38: 563–595.
17. Kurtiz SJ Landis JR Koch GG. A general overview of Mantel-Haenszel methods: Applications and recent developments. Ann Rev Pub Health. 1988; 9: 123–160.
18. Koch GG Sollecito WA. Statistical considerations in the design, analysis, and interpretation of comparative clinical studies: An academic perspective. Drug Inf J. 1984; 18: 131–151.
19. Fleiss JL. The Design and Analysis of Clinical Experiments. New York: Wiley; 1986.
20. Holm S. A simple sequentially rejective multiple test procedure. Scandinavian J Stat. 1979; 6: 65–70.
21. Shaffer J. Modified sequentially rejective multiple test problems. J Am Stat Assoc. 1986; 81: 826–831.
22. Hailperin R. Best possible inequalities for the probability of a logical function of events. Am Math Monthly. 1965; 72: 343–359.
23. Rüger B. Das maximale signifikanzniveau des tests: “Lehne H0 ab, wenn k unter n gegebenen tests zur ablehnung führen.” Metrika. 1978; 25: 171–178.
24. Westfall PH Young SS. Resampling-based Multiple Comparison Testing: Examples and Methods for p-Value Adjustment. New York: Wiley; 1993.
25. Lachin J. Some large-sample distribution-free estimators and tests for multivariate, partially incomplete data from two populations. Stat Med. 1992; 11: 1151–1170.
26. Gillings D Koch GG. The application of intention-to-treat to the analysis of clinical trials. Drug Inf J. 1991; 25: 411–424.